ICYMI: Insurer: “Can drugs as expensive as these really be cost-effective? The answer is yes.”

06.25.14 | By

The focus in recent weeks on the cost of a new cure for Hepatitis C has largely ignored the long-term value it provides to patients and the health care system broadly, including helping to prevent expensive hospitalizations and costly medical procedures, such as liver transplants.

Restricting Access to Medicines At the Expense of Patients Warrants a Candid Conversation

06.23.14 | By

It has become increasingly clear in recent weeks that far too many patients simply cannot access innovative medicines that help treat costly chronic diseases. While more Americans now have health care coverage under the Affordable Care Act (ACA), they still face insurmountable barriers to access that hinder our collective efforts to prevent, manage, and cure these conditions.

Investments in Innovation, Jobs, and Economic Development

06.20.14 | By

Innovation is the engine of economic growth and development.  Research and development (R&D) spending is what creates jobs and makes innovation a reality.  As the global economy continues to recover and regain its former strength, the pharmaceutical industry remains the world’s largest source of R&D spending.  According to a recent article in the

Week in Review: The Importance of Patient Perspectives

06.20.14 | By

“The biopharmaceutical industry’s top priority is to provide patients with access to innovative, life-saving medicines.”

Over 3 Million Dollars Available for Young Scientists

06.19.14 | By

For nearly 50 years the PhRMA Foundation has helped thousands of scientists advance their careers and has inspired new generations to enter biopharmaceutical research. The early-career support provided by the PhRMA Foundation has been a catalyst for scientists to become leaders in their organizations and fields. Their programs help build a larger pool of highly-trained researchers to meet the growing needs of academic institutions, the government and the research-intensive pharmaceutical industry. Are you one of them?

First Technology Pilot Program Shares Perspective of Sickle Cell Disease Community with FDA

06.18.14 | By

In the guest blog below, Michele Lloyd-Puryear, Special Consultant to Genetic Alliance, discusses key findings from a patient-driven data collection effort intended to complement the Food and Drug Administration’s (FDA) patient-focused drug development initiative which was part of the most recent reauthorization of the Prescription Drug User Fee Act.

Patient Reported Outcomes as a Means to Reaching Effective Quality Measurement

06.17.14 | By

A recent Roundtable in Washington D.C. underscored why, with the growing focus on value-based payment in health care, it’s more important than ever to focus on the patient. We can’t advance patient-centered care if we aren’t measuring and incentivizing what matters to patients. We have begun to see this shift in the premarket arena via patient-focused drug development and in comparative effectiveness research at the Patient-Centered Outcomes Research Institute.

Week in Review: The Obstacles to Patient Care Under HIX

06.13.14 | By

For our nation’s most vulnerable patients, access to necessary medicines to treat and even cure the diseases they are battling every day is critical. Improved patient health relies on the innovative treatments, and this week we focused on the importance of ensuring those medicines make it into the hands of patients in need.

Working Together for the Greater Good: The Current State of the Collaborative Research Ecosystem in Oncology

06.12.14 | By

Keeping the spirit of innovation alive in the oncology field is paramount to future scientific advances and finding cures. An essential element of innovation is collaboration. Relevant stakeholders coming together and pooling collective knowledge together can ignite the fire that becomes the next big thing to improve the lives of cancer patients.

Some Health Insurance Exchange Plans Put All Treatments for Certain Diseases on Top Cost-Sharing Tier

06.11.14 | By

This morning at the National Press Club, PhRMA CEO John J. Castellani joined patient groups to release new research from Avalere Health.

Pages

Subscribe to RSS - Opinion